logo
'I adopted a dog from a man I met on the street whose landlord didn't allow pets'

'I adopted a dog from a man I met on the street whose landlord didn't allow pets'

Irish Examiner22-07-2025
Several years ago, I spontaneously adopted a beautiful dog from a man I met on the street.
We were on the waterfront in Cobh, and the young man was pleading (via a sign) for someone to take his beloved lurcher as the landlord of his new flat forbade dogs.
As I was building in the countryside and urgently seeking a companion for another rescue, I told him I would take her to paradise.
It was a lucky day for me, but that guy was left bereft and weeping as I drove away with his cherished pet.
He knew he was welcome to come and see her at any time, and he called me to check on her progress on several occasions.
Kya's daughter Faelen with their adopted lurcher Yemaya. Picture: Kya deLongchamps
Yemaya was about six years old when we adopted her, and following spaying and microchipping, she lived happily for another ten years, until 2011.
During her time with us, she was also delighted to act as foster mother to several other animals we took on through the Cork Society for the Prevention of Cruelty to Animals (CSPCA).
Yemaya, pictured in winter 2010 with Kya's husband Charlie and their daughter Faelen, was adored by the entire family. Picture: Kya deLongchamps
Renting with a pet in tow presents particular problems, as it is completely at the discretion of your landlord.
Dogs Trust Ireland has reported a 112% rise over 5 years in the number of people giving up their pets because their new home won't allow pets of any kind (restricted or otherwise).
Given that only 7% of rental properties advertised on Daft allow pets, it's no surprise.
Dogs Trust Ireland has reported a 112% rise over five years in the number of people giving up their pets. File picture
Dogs Trust Ireland received over 400 calls from distraught owners who could not find accommodation to suit in 2024. It has multiple stories to share about the distress of being faced with this heartbreaking situation, fighting for the right to keep animals that most people regard as nothing short of family.
One duo who faced this struggle is Celia Madrid Delgado and her dog Kai, reports the charity. 'Celia works as a canine carer at our re-homing centre in Dublin and had to apply to 300 properties before she found a rental home that would allow Kai,' according to Dogs Trust Ireland.
The charity has set up a petition to demand government offer more flexible rental agreements for pet owners while protecting landlords from disruptive, destructive, or unsafe situations that could raise liability issues. For a link to the petition, go to Dogstrust.ie. The website also offers a useful list for landlords who might consider renting their property to a pet owner, with a list of recommendations.
If you are renting or have rented in the past, try to secure a positive behaviour review for your dog or cat from your landlord, as this might prove a clincher in persuading an uncertain owner to let to you. An assurance that the property you rented previously was also kept in good order would be ideal.
Generally, if you are ultimately forced to give up a dog, cat, bird or small furry, contact your local authority kennels or recognised animal charities first, and don't forget to ask for the help of your vet in sourcing a suitable new home. They may know someone whose heart and front door is wide open.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs
Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs

Yahoo

time2 minutes ago

  • Yahoo

Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs

Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal challenge from a lawsuit filed in Texas that accuses the pharma company of bribing providers to prescribe its drugs. Attorney General for Texas Ken Paxton and Health Choice Alliance claim Eli Lilly 'offered illegal incentives' to medical providers in the southern state so its most profitable drugs, including popular glucagon-like peptide-1 receptor agonist (GLP-1RA) medications tirzepatide, marketed as Mounjaro and Zepbound, would be preferentially prescribed to patients. The lawsuit marks the latest legal assault by the attorney general's office, having previously sued Eli Lilly over an industry conspiracy to increase insulin prices. Health Choice Alliance has also filed previous legal action against Eli Lilly in the past. In the latest filing, Paxton and Health Choice Alliance claim that Eli Lilly's actions cost Texas Medicaid 'millions of dollars'. The claimants argue that prescriptions were covered by the government insurance programme, resulting in claims to Texas Medicaid that were 'tainted by Eli Lilly's illegal marketing and quid pro quo arrangements'. As per the filing, Lilly is alleged to have participated in two schemes to induce and influence providers. In the first, the pharma company, with the help of third parties, apparently provided free nursing services. The second scheme alleges that Lilly continues to offer reimbursement support services to get their drugs prescribed over rivals. An Eli Lilly spokesperson told Pharmaceutical Technology that it intends to 'vigorously defend against these allegations'. The spokesperson added: 'Multiple courts and the federal government have rejected claims by this same corporate relator against Lilly as meritless. In fact, the United States Government determined that 'the relators' allegations lack sufficient factual and legal support' in a prior case, explaining that federal healthcare programs have a strong interest in ensuring that, after a physician has appropriately prescribed a medication, patients have access to basic product support relating to their medication." This referred to similar kickback claims previously made by Health Choice Alliance. Lilly was originally sued by the organisation in 2017, alleged to have participated in a 'multi-tiered kickback scheme' along with other pharma companies, including Bayer. This involved offering free nursing services in exchange for preferential drug prescriptions. The case was dismissed a year later by a judge in Texas. In 2021, a court of appeals upheld the prior decision to scrap the case amid attempts to revive the lawsuit. It is also not the first time the state of Texas has accused Lilly of unlawful activities. In October 2024, the attorney general's office sued several drugmakers and pharmacy benefit managers (PBMs) over insulin product prices. According to a statement at the time, Paxton accused manufacturers of a 'conspiracy' to artificially and willingly raise insulin prices and then pay an undisclosed amount back to PBMs in a quid pro quo arrangement. Lilly had a strong Q2 as it extended its lead over rival Novo Nordisk in the GLP-1RA treatment space. The company reported growth of 172% and 68% for Zepbound and Mounjaro, respectively. The two drugs brought in combined sales of $8.57bn in the quarter. "Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

Why CoreWeave is getting hit hard: Opening Bid top takeaway
Why CoreWeave is getting hit hard: Opening Bid top takeaway

Yahoo

time2 minutes ago

  • Yahoo

Why CoreWeave is getting hit hard: Opening Bid top takeaway

A market hooked on rate cut hopes. It's 35 days until the next Federal Reserve meeting, and investors are banking on a September rate cut. Currently, there's a 98.2% probability the Fed cuts rates at that meeting, according to the CME FedWatch tool. The probability got a boost on Tuesday following a Consumer Price Index reading that didn't signal accelerating tariff-driven inflation. Another side of the trade does exist, however. I know this may come as a shock to you, but not every stock in this market is ripping higher. Take a look at the plunges in Cava (CAVA) and CoreWeave (CRWV) today in the wake of their earnings last night. The poundings should serve as a reminder that in a hot market, no disappointments on an earnings day will be tolerated. No letdowns in sales. No letdowns in earnings. Not letdown in guidance. Reports must be darn near perfect, or else! Stock analysis: CoreWeave CoreWeave was teed up to let down investors last night. And it did on several fronts, with the stock tanking 15% today. First, the company's net loss was much higher than consensus. Second, capital expenditures were a whopping $1 billion higher sequentially. And third, capex may climb another $500 million in the current quarter. While I appreciate the company's revenue backlog of $30.1 billion doubled year over year, the company's mixed results and high debt load are real causes for concern. Here are two important call-outs this morning from DA Davidson analyst Gil Luria. I'm highlighting them because most on the Street have stayed bullish on CoreWeave post earnings, citing strong fundamentals. Luria presents a valid bear case. "With operating income of $200 million and interest expense of $(267 million) it appears that CoreWeave does not currently generate enough profit to pay all its debt holders, certainly not equity holders. Guidance of $(350)-(390) million of interest expense on only $160-190 million of operating income indicates that may be getting worse." "CoreWeave will likely need to add $10 billion more debt during the balance of the year to support their data center expansion plans. Management acknowledges that they will have to bring more debt onto the balance sheet in order to scale this business further, and we believe they will have to perform significant capital raises in the near-term just to meet their guidance and capacity commitments." Zoom-in: A Starbucks milestone A year ago today, I remember jumping out of my chair in astonishment as news broke that then-Chipotle (CMG) CEO Brian Niccol was named the new CEO of Starbucks (SBUX). I found the news mind-blowing for 75 different reasons, but I will offer two. For one, I just interviewed Niccol a few weeks prior — and definitely didn't get the sense he was ready to leave the burrito kingdom he had built. Two, while struggling and feeling the heat, Starbucks' then-CEO Laxman Narasimhan was still relatively new on the job. The stock surged 20% on the news. Niccol is one of the most highly regarded restaurant execs of the past 20 years. Since the appointment, Niccol has brought back condiment bars. Pared back items on the menu. Tried to bring down mobile order wait times. He has put the China business up for review. New menu items will hit stores soon, such as coconut water infused coffee. The overall business hasn't turned the corner (and the stock price is back to where it was one year ago today), but the pump is primed for better results over the next 12 months. The stock's valuation reflects that hope. Here is Brian in his own words: "I think there were some choices made before me that really set us back on our ability to create that great customer connection between our barista and customer ... And so that's really why we created the Green Apron service model. It's all around basically providing the right labor in store so that our partners have the right amount of time to execute the tasks that they need to execute." Brian Sozzi is Yahoo Finance's Executive Editor and a member of Yahoo Finance's editorial leadership team. Follow Sozzi on X @BrianSozzi, Instagram, and LinkedIn. Tips on stories? Email Click here for in-depth analysis of the latest stock market news and events moving stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Affirm Expands Buy Now, Pay Later To In-Store Purchases Via Stripe Terminal
Affirm Expands Buy Now, Pay Later To In-Store Purchases Via Stripe Terminal

Yahoo

time2 minutes ago

  • Yahoo

Affirm Expands Buy Now, Pay Later To In-Store Purchases Via Stripe Terminal

Affirm Holdings, Inc. (NASDAQ:AFRM) shares are trading higher on Wednesday. The company and Stripe are extending their collaboration to the checkout counter, introducing buy now, pay later at the point of sale through Stripe Terminal. The firm said its in-person BNPL option is now available on Stripe Terminal across the U.S. and Canada, giving merchants a unified way to offer pay-over-time both online and in stores via a network of more than one million checkout on Stripe Terminal, shoppers can select 'Pay with Affirm,' scan a code with their phone, complete a quick eligibility step, and, if approved, choose customized installment plans. Financing windows range from roughly one month to five years and are designed to accommodate purchases from about $35 up to $30,000. Affirm says it approves only amounts it believes customers can responsibly repay and does not levy late or hidden fees. 'We're excited to deepen our multi-year partnership with Stripe and bring Affirm to more shoppers via Stripe's in-person payment solution,' said Wayne Pommen, Chief Revenue Officer at Affirm. 'With over 80% of retail spend still happening in physical stores, enabling Affirm through Stripe Terminal gives us a powerful new way to help merchants drive growth and meet customers where they are – with more choice, transparency, and control at checkout.' The move brings BNPL to physical retail at scale, potentially lifting conversion and ticket sizes for merchants that already use Stripe online. For Affirm, the expansion broadens distribution without requiring separate hardware or onboarding, while retailers benefit from a consistent customer flow across digital and in-store channels. The integration is live for eligible U.S. and Canadian sellers using Stripe Terminal. Stripe customers can find setup details on Stripe's resources and documentation pages. Price Action: AFRM shares are trading higher by 1.15% to $77.77 at last check Wednesday. Read Next:Photo via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Affirm Expands Buy Now, Pay Later To In-Store Purchases Via Stripe Terminal originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store